New pharmacological agents, including sodium-glucose co-transporter type 3 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP4) inhibitors, and glucagon-like peptide-1 receptor agonist (GLP-1 RA) may have effects beyond glycemic control pertinent to cardiovascular risk reduction in diabetes (134). This evidence concerns the gene GLP1R and diabetes mellitus.